ISSWSH Fall Course 2019
ISSWSH Annual Meeting 2020
March 5-8, 2020 114 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA
ISSWSH Sexual Pain Course 2020
April 17-18, 2020 157 days left
Georgetown University Medical Center, Medical and Dental Building, Washington, DC, USA
ISSWSH Annual Meeting 2021
March 4-7, 2021 478 days left
Renaissance Dallas Hotel, Dallas, TX, USA
ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.
A recently published health report on HSDD treatments was poorly researched, contained elements of bias, and perpetuated inaccuracies about the condition.
We, the Executive Committee of the International Society for the Study of Women’s Sexual Health (www.isswsh.org) write this response to an article published on May 8, 2019 on CNN Health entitled “Drug Campaign Touts 'Female Viagra' in the Name of Equality” by Rachel Bluth of Kaiser Health News (https://edition.cnn.com/2019/05/08/health/women-libido-addyi-partner/index.html). As a scientific and medical society dedicated to supporting research, education, and clinical care for women’s sexual health, ISSWSH encourages informed discussion on disease states impacting sexual health. We also understand that there may be valid critiques of how some pharmaceutical companies conduct their marketing campaigns. Nevertheless, we found the article in question to be poorly researched and especially biased.Read more ...
It is with great sadness we announce the loss of one of our sexual medicine colleagues, Marcel Waldinger, on May 1. Dr. Waldinger was a long time member of ISSWSH, most recently serving on the consensus panel for Persistent Genital Arousal Disorder (PGAD). His landmark work in this area, caring for patients and examining the retaionship between PGAD and Restless Leg Syndrome will be included in the consensus document from this panel. Thus his work will continue posthumously. Dr. Waldinger will also be remembered for his work in the area of premature ejaculation, helping to develop the content of measuring intravaginal ejaculatory latency time (IELT) used in premature ejaculation clinical trials. He was passionate about his work and about helping his patients, working cooperatively to further knowledge in the field.Read more ...